Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 15/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 0.84 |
| ▸ | MMP9 | P14780 | 3/20 | 0.84 |
| ▸ | MMP8 | P22894 | 3/20 | 0.84 |
| ▸ | MMP13 | P45452 | 3/20 | 0.84 |
| ▸ | CASP3 | P42574 | 2/20 | 0.84 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.84 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.84 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982761 | 0.93 | NPC1 (0.97) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31474755 | 0.92 | NPBWR1 (0.85) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20982700 | 0.91 | NPC1 (0.94) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5566191 | 0.91 | NPC1 (1.00) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3193088 | 0.89 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3190883 | 0.86 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3183544 | 0.86 | NPC1 (0.84) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10117321 | 0.86 | NPBWR1 (1.00) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL17898263 | 0.86 | NPBWR1 (1.00) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31049578 | 0.86 | NPBWR1 (1.00) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| CN-118416058-A | Application of benzimidazole compound | 广州市朝利良生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230348436-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230348436-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-11-02 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | NPBWR1 323/4885NPC1 4082/4885MAPT 4542/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885NPC1 2477/4885MAPT 3113/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | NPBWR1 323/4885NPC1 4082/4885MAPT 4542/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885NPC1 2477/4885MAPT 3113/4885 |
| US-20230348436-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | DOT1L, HAT1, UQCRB | NPBWR1 1416/4885NPC1 946/4885MAPT 2454/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885NPC1 3637/4885MAPT 4858/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885NPC1 3637/4885MAPT 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.